Q1 EPS Forecast for Solid Biosciences Boosted by Analyst

Solid Biosciences Inc. (NASDAQ:SLDB) – Equities research analysts at HC Wainwright upped their Q1 2025 EPS estimates for shares of Solid Biosciences in a research report issued on Monday, March 10th. HC Wainwright analyst A. He now anticipates that the company will post earnings of ($0.43) per share for the quarter, up from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at $1.14 EPS.

Other analysts also recently issued research reports about the company. Truist Financial initiated coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price objective on the stock. Citizens Jmp upgraded Solid Biosciences to a “strong-buy” rating in a report on Tuesday, December 10th. Wedbush initiated coverage on Solid Biosciences in a research report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price target for the company. JMP Securities began coverage on shares of Solid Biosciences in a research note on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research note on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $15.80.

Solid Biosciences Trading Up 2.1 %

Shares of SLDB stock opened at $5.73 on Wednesday. The stock has a market capitalization of $437.31 million, a price-to-earnings ratio of -1.88 and a beta of 1.98. Solid Biosciences has a 12-month low of $2.88 and a 12-month high of $15.05. The stock’s 50-day moving average price is $4.12 and its 200-day moving average price is $5.47.

Institutional Investors Weigh In On Solid Biosciences

A number of institutional investors have recently added to or reduced their stakes in SLDB. Vestal Point Capital LP boosted its stake in Solid Biosciences by 1.8% in the fourth quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company’s stock valued at $11,400,000 after acquiring an additional 50,000 shares in the last quarter. JPMorgan Chase & Co. increased its position in Solid Biosciences by 9,393.8% during the 4th quarter. JPMorgan Chase & Co. now owns 955,932 shares of the company’s stock valued at $3,824,000 after buying an additional 945,863 shares in the last quarter. Redmile Group LLC acquired a new position in Solid Biosciences during the 4th quarter valued at about $2,461,000. Geode Capital Management LLC raised its stake in Solid Biosciences by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 509,802 shares of the company’s stock valued at $2,040,000 after buying an additional 4,932 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in Solid Biosciences by 292.8% in the third quarter. Point72 Asset Management L.P. now owns 443,010 shares of the company’s stock worth $3,088,000 after acquiring an additional 330,234 shares in the last quarter. Institutional investors own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.